1887

Abstract

The herpes simplex type 2 (HSV-2) envelope glycoprotein (gD2) was evaluated as a potential antigen candidate for a plasmid DNA (pDNA)-based HSV-2 vaccine. The pDNA was formulated with Vaxfectin, a cationic lipid-based adjuvant, and tested in a murine HSV-2 lethal challenge model. gD2 was expressed as full-length (FL) and secreted (S) gD2 forms. A 0.1 µg pDNA dose was tested to distinguish treatment conditions for survival and a 100 µg pDNA dose was tested to distinguish treatment conditions for reduction in vaginal and latent HSV-2 copies. Vaxfectin-formulated gD2 pDNA significantly increased serum IgG titres and survival for both FL gD2 and S gD2 compared with gD2 pDNA alone. Mice immunized with FL gD2 formulated with Vaxfectin showed reduction in vaginal and dorsal root ganglia (DRG) HSV-2 copies. The stringency of this protection was further evaluated by testing Vaxfectin-formulated FL gD2 pDNA at a high 500 LD inoculum. At this high viral challenge, the 0.1 µg dose of FL gD2 Vaxfectin-formulated pDNA yielded 80 % survival compared with no survival for FL gD2 pDNA alone. Vaxfectin-formulated FL gD2 pDNA, administered at a 100 µg pDNA dose, significantly reduced HSV-2 DNA copy number, compared with FL gD2 DNA alone. In addition, 40 % of mice vaccinated with adjuvanted FL pDNA had no detectable HSV-2 viral genomes in the DRG, whereas all mice vaccinated with gD2 pDNA alone were positive for HSV-2 viral genomes. These results show the potential contribution of Vaxfectin-gD2 pDNA to a future multivalent HSV-2 vaccine.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.040055-0
2012-06-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/6/1305.html?itemId=/content/journal/jgv/10.1099/vir.0.040055-0&mimeType=html&fmt=ahah

References

  1. Aumakhan B. , Hardick A. , Quinn T. C. , Laeyendecker O. , Gange S. J. , Beyrer C. , Cox C. , Anastos K. , Cohen M. . & other authors ( 2010; ). Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. . Virol J 7:, 328. [CrossRef] [PubMed]
    [Google Scholar]
  2. Balachandran N. , Bacchetti S. , Rawls W. E. . ( 1982; ). Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. . Infect Immun 37:, 1132–1137.[PubMed]
    [Google Scholar]
  3. Belshe R. B. , Leone P. A. , Bernstein D. I. , Wald A. , Levin M. J. , Stapleton J. T. , Gorfinkel I. , Morrow R. L. , Ewell M. G. . & other authors ( 2012; ). Efficacy results of a trial of a herpes simplex vaccine. . N Engl J Med 366:, 34–43. [CrossRef] [PubMed]
    [Google Scholar]
  4. BenMohamed L. , Bertrand G. , McNamara C. D. , Gras-Masse H. , Hammer J. , Wechsler S. L. , Nesburn A. B. . ( 2003; ). Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. . J Virol 77:, 9463–9473. [CrossRef] [PubMed]
    [Google Scholar]
  5. Bernstein D. I. , Aoki F. Y. , Tyring S. K. , Stanberry L. R. , St-Pierre C. , Shafran S. D. , Leroux-Roels G. , Van Herck K. , Bollaerts A. , Dubin G. . Glaxo Smith Kline Herpes Vaccine Study Group ( 2005; ). Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. . Clin Infect Dis 40:, 1271–1281. [CrossRef] [PubMed]
    [Google Scholar]
  6. Bourne N. , Milligan G. N. , Schleiss M. R. , Bernstein D. I. , Stanberry L. R. . ( 1996; ). DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. . Vaccine 14:, 1230–1234. [CrossRef] [PubMed]
    [Google Scholar]
  7. Bourne N. , Pyles R. B. , Bernstein D. I. , Stanberry L. R. . ( 2002; ). Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. . J Gen Virol 83:, 2797–2801.[PubMed]
    [Google Scholar]
  8. Bourne N. , Milligan G. N. , Stanberry L. R. , Stegall R. , Pyles R. B. . ( 2005; ). Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. . J Infect Dis 192:, 2117–2123. [CrossRef] [PubMed]
    [Google Scholar]
  9. Cattamanchi A. , Posavad C. M. , Wald A. , Baine Y. , Moses J. , Higgins T. J. , Ginsberg R. , Ciccarelli R. , Corey L. , Koelle D. M. . ( 2008; ). Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. . Clin Vaccine Immunol 15:, 1638–1643. [CrossRef] [PubMed]
    [Google Scholar]
  10. Chen C. Y. , Ballard R. C. , Beck-Sague C. M. , Dangor Y. , Radebe F. , Schmid S. , Weiss J. B. , Tshabalala V. , Fehler G. . & other authors ( 2000; ). Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. . Sex Transm Dis 27:, 21–29. [CrossRef] [PubMed]
    [Google Scholar]
  11. Chentoufi A. A. , Zhang X. , Lamberth K. , Dasgupta G. , Bettahi I. , Nguyen A. , Wu M. , Zhu X. , Mohebbi A. . & other authors ( 2008; ). HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. . J Immunol 180:, 426–437.[PubMed] [CrossRef]
    [Google Scholar]
  12. Coen D. M. , Kosz-Vnenchak M. , Jacobson J. G. , Leib D. A. , Bogard C. L. , Schaffer P. A. , Tyler K. L. , Knipe D. M. . ( 1989; ). Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. . Proc Natl Acad Sci U S A 86:, 4736–4740. [CrossRef] [PubMed]
    [Google Scholar]
  13. Cohen J. . ( 2010; ). Immunology. Painful failure of promising genital herpes vaccine. . Science 330:, 304. [CrossRef] [PubMed]
    [Google Scholar]
  14. Corey L. , Langenberg A. G. , Ashley R. , Sekulovich R. E. , Izu A. E. , Douglas J. M. Jr , Handsfield H. H. , Warren T. , Marr L. . & other authors ( 1999; ). Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. . JAMA 282:, 331–340. [CrossRef] [PubMed]
    [Google Scholar]
  15. Corey L. , Wald A. , Celum C. L. , Quinn T. C. . ( 2004; ). The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. . J Acquir Immune Defic Syndr 35:, 435–445. [CrossRef] [PubMed]
    [Google Scholar]
  16. Dolan A. , Jamieson F. E. , Cunningham C. , Barnett B. C. , McGeoch D. J. . ( 1998; ). The genome sequence of herpes simplex virus type 2. . J Virol 72:, 2010–2021.[PubMed]
    [Google Scholar]
  17. Donnelly J. J. , Ulmer J. B. , Liu M. A. . ( 1997; ). DNA vaccines. . Life Sci 60:, 163–172. [CrossRef] [PubMed]
    [Google Scholar]
  18. Fló J. . ( 2003; ). Co-immunization with plasmids coding the full length and a soluble form of glycoprotein D of HSV-2 induces protective cellular and humoral immune response in mice. . Vaccine 21:, 1239–1245. [CrossRef] [PubMed]
    [Google Scholar]
  19. Hartikka J. , Sawdey M. , Cornefert-Jensen F. , Margalith M. , Barnhart K. , Nolasco M. , Vahlsing H. L. , Meek J. , Marquet M. . & other authors ( 1996; ). An improved plasmid DNA expression vector for direct injection into skeletal muscle. . Hum Gene Ther 7:, 1205–1217. [CrossRef] [PubMed]
    [Google Scholar]
  20. Hartikka J. , Bozoukova V. , Ferrari M. , Sukhu L. , Enas J. , Sawdey M. , Wloch M. K. , Tonsky K. , Norman J. . & other authors ( 2001; ). Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. . Vaccine 19:, 1911–1923. [CrossRef] [PubMed]
    [Google Scholar]
  21. Hermanson G. , Whitlow V. , Parker S. , Tonsky K. , Rusalov D. , Ferrari M. , Lalor P. , Komai M. , Mere R. . & other authors ( 2004; ). A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. . Proc Natl Acad Sci U S A 101:, 13601–13606. [CrossRef] [PubMed]
    [Google Scholar]
  22. Higgins T. J. , Herold K. M. , Arnold R. L. , McElhiney S. P. , Shroff K. E. , Pachuk C. J. . ( 2000; ). Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. . J Infect Dis 182:, 1311–1320. [CrossRef] [PubMed]
    [Google Scholar]
  23. Hosken N. , McGowan P. , Meier A. , Koelle D. M. , Sleath P. , Wagener F. , Elliott M. , Grabstein K. , Posavad C. , Corey L. . ( 2006; ). Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. . J Virol 80:, 5509–5515. [CrossRef] [PubMed]
    [Google Scholar]
  24. Iijima N. , Linehan M. M. , Zamora M. , Butkus D. , Dunn R. , Kehry M. R. , Laufer T. M. , Iwasaki A. . ( 2008; ). Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. . J Exp Med 205:, 3041–3052. [CrossRef] [PubMed]
    [Google Scholar]
  25. Jimenez G. S. , Planchon R. , Wei Q. , Rusalov D. , Geall A. , Enas J. , Lalor P. , Leamy V. , Vahle R. . & other authors ( 2007; ). Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. . Hum Vaccin 3:, 157–164. [CrossRef] [PubMed]
    [Google Scholar]
  26. Jing L. , McCaughey S. M. , Davies D. H. , Chong T. M. , Felgner P. L. , De Rosa S. C. , Wilson C. B. , Koelle D. M. . ( 2009; ). ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. . J Immunol Methods 347:, 36–45. [CrossRef] [PubMed]
    [Google Scholar]
  27. Kask A. S. , Chen X. , Marshak J. O. , Dong L. , Saracino M. , Chen D. , Jarrahian C. , Kendall M. A. , Koelle D. M. . ( 2010; ). DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. . Vaccine 28:, 7483–7491. [CrossRef] [PubMed]
    [Google Scholar]
  28. Kemble G. , Spaete R. . ( 2007; ). Herpes simplex vaccines. . In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, chapter 69. Edited by Arvin A. , Campadelli-Fiume G. , Mocarski E. , Moore P. S. , Roizman B. , Whitley R. , Yamanishi K. . . Cambridge:: Cambridge University Press;.
    [Google Scholar]
  29. Kim M. , Taylor J. , Sidney J. , Mikloska Z. , Bodsworth N. , Lagios K. , Dunckley H. , Byth-Wilson K. , Denis M. . & other authors ( 2008; ). Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. . J Immunol 181:, 6604–6615.[PubMed] [CrossRef]
    [Google Scholar]
  30. Klein R. J. . ( 1980; ). Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice. . J Gen Virol 49:, 401–405. [CrossRef] [PubMed]
    [Google Scholar]
  31. Koelle D. M. , Corey L. . ( 2008; ). Herpes simplex: insights on pathogenesis and possible vaccines. . Annu Rev Med 59:, 381–395. [CrossRef] [PubMed]
    [Google Scholar]
  32. Koelle D. M. , Benedetti J. , Langenberg A. , Corey L. . ( 1992; ). Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. . Ann Intern Med 116:, 433–437.[PubMed] [CrossRef]
    [Google Scholar]
  33. Koelle D. M. , Liu Z. , McClurkan C. L. , Cevallos R. C. , Vieira J. , Hosken N. A. , Meseda C. A. , Snow D. C. , Wald A. , Corey L. . ( 2003; ). Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. . Proc Natl Acad Sci U S A 100:, 12899–12904. [CrossRef] [PubMed]
    [Google Scholar]
  34. Langenberg A. G. , Burke R. L. , Adair S. F. , Sekulovich R. , Tigges M. , Dekker C. L. , Corey L. . ( 1995; ). A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. . Ann Intern Med 122:, 889–898.[PubMed] [CrossRef]
    [Google Scholar]
  35. Long D. , Madara T. J. , Ponce de Leon M. , Cohen G. H. , Montgomery P. C. , Eisenberg R. J. . ( 1984; ). Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. . Infect Immun 43:, 761–764.[PubMed]
    [Google Scholar]
  36. Malin S. A. , Davis B. M. , Molliver D. C. . ( 2007; ). Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. . Nat Protoc 2:, 152–160. [CrossRef] [PubMed]
    [Google Scholar]
  37. Manickan E. , Rouse R. J. , Yu Z. , Wire W. S. , Rouse B. T. . ( 1995; ). Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. . J Immunol 155:, 259–265.[PubMed]
    [Google Scholar]
  38. Margalith M. , Vilalta A. . ( 2006; ). Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. . Genet Vaccines Ther 4:, 2. [CrossRef] [PubMed]
    [Google Scholar]
  39. McClements W. L. , Armstrong M. E. , Keys R. D. , Liu M. A. . ( 1996; ). Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. . Proc Natl Acad Sci U S A 93:, 11414–11420. [CrossRef] [PubMed]
    [Google Scholar]
  40. Muller W. J. , Dong L. , Vilalta A. , Byrd B. , Wilhelm K. M. , McClurkan C. L. , Margalith M. , Liu C. , Kaslow D. . & other authors ( 2009; ). Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. . J Gen Virol 90:, 1153–1163. [CrossRef] [PubMed]
    [Google Scholar]
  41. Nass P. H. , Elkins K. L. , Weir J. P. . ( 2001; ). Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. . Vaccine 19:, 1538–1546. [CrossRef] [PubMed]
    [Google Scholar]
  42. Pan C. H. , Jimenez G. S. , Nair N. , Wei Q. , Adams R. J. , Polack F. P. , Rolland A. , Vilalta A. , Griffin D. E. . ( 2008; ). Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. . Clin Vaccine Immunol 15:, 1214–1221. [CrossRef] [PubMed]
    [Google Scholar]
  43. Parr M. B. , Kepple L. , McDermott M. R. , Drew M. D. , Bozzola J. J. , Parr E. L. . ( 1994; ). A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. . Lab Invest 70:, 369–380.[PubMed]
    [Google Scholar]
  44. Perez G. , Skurnick J. H. , Denny T. N. , Stephens R. , Kennedy C. A. , Regivick N. , Nahmias A. , Lee F. K. , Lo S. C. . & other authors ( 1998; ). Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. . Int J Infect Dis 3:, 5–11. [CrossRef] [PubMed]
    [Google Scholar]
  45. Rajcáni J. , Mosko T. , Rezuchová I. . ( 2005; ). Current developments in viral DNA vaccines: shall they solve the unsolved?. Rev Med Virol 15:, 303–325. [CrossRef] [PubMed]
    [Google Scholar]
  46. Reyes L. , Hartikka J. , Bozoukova V. , Sukhu L. , Nishioka W. , Singh G. , Ferrari M. , Enas J. , Wheeler C. J. . & other authors ( 2001; ). Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. . Vaccine 19:, 3778–3786. [CrossRef] [PubMed]
    [Google Scholar]
  47. Sawtell N. M. . ( 1998; ). The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. . J Virol 72:, 6888–6892.[PubMed]
    [Google Scholar]
  48. Sawtell N. M. , Poon D. K. , Tansky C. S. , Thompson R. L. . ( 1998; ). The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. . J Virol 72:, 5343–5350.[PubMed]
    [Google Scholar]
  49. Sawtell N. M. , Thompson R. L. , Stanberry L. R. , Bernstein D. I. . ( 2001; ). Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. . J Infect Dis 184:, 964–971. [CrossRef] [PubMed]
    [Google Scholar]
  50. Shiver J. W. , Fu T. M. , Chen L. , Casimiro D. R. , Davies M. E. , Evans R. K. , Zhang Z. Q. , Simon A. J. , Trigona W. L. . & other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. . Nature 415:, 331–335. [CrossRef] [PubMed]
    [Google Scholar]
  51. Simmons A. , Nash A. A. . ( 1985; ). Role of antibody in primary and recurrent herpes simplex virus infection. . J Virol 53:, 944–948.[PubMed]
    [Google Scholar]
  52. Sin J. I. , Ayyavoo V. , Boyer J. , Kim J. , Ciccarelli R. B. , Weiner D. B. . ( 1999; ). Protective immune correlates can segregate by vaccine type in a murine herpes model system. . Int Immunol 11:, 1763–1773. [CrossRef] [PubMed]
    [Google Scholar]
  53. Sin J. , Kim J. J. , Pachuk C. , Satishchandran C. , Weiner D. B. . ( 2000; ). DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4+ T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. . J Virol 74:, 11173–11180. [CrossRef] [PubMed]
    [Google Scholar]
  54. Sin J. I. , Kim J. J. , Zhang D. , Weiner D. B. . ( 2001; ). Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. . Hum Gene Ther 12:, 1091–1102. [CrossRef] [PubMed]
    [Google Scholar]
  55. Smith L. R. , Wloch M. K. , Ye M. , Reyes L. R. , Boutsaboualoy S. , Dunne C. E. , Chaplin J. A. , Rusalov D. , Rolland A. P. . & other authors ( 2010; ). Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. . Vaccine 28:, 2565–2572. [CrossRef] [PubMed]
    [Google Scholar]
  56. Stanberry L. R. , Spruance S. , Cunningham A. L. , Bernstein D. I. , Mindel A. , Sacks S. , Tyring S. , Aoki F. Y. , Slaoui M. . & other authors ( 2002; ). Glycoprotein-D–adjuvant vaccine to prevent genital herpes. . N Engl J Med 347:, 1652–1661. [CrossRef] [PubMed]
    [Google Scholar]
  57. Sullivan S. M. , Doukas J. , Hartikka J. , Smith L. , Rolland A. . ( 2010; ). Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. . Expert Opin Drug Deliv 7:, 1433–1446. [CrossRef] [PubMed]
    [Google Scholar]
  58. Ulmer J. B. , DeWitt C. M. , Chastain M. , Friedman A. , Donnelly J. J. , McClements W. L. , Caulfield M. J. , Bohannon K. E. , Volkin D. B. , Evans R. K. . ( 1999; ). Enhancement of DNA vaccine potency using conventional aluminum adjuvants. . Vaccine 18:, 18–28. [CrossRef] [PubMed]
    [Google Scholar]
  59. Vilalta A. , Shlapobersky M. , Wei Q. , Planchon R. , Rolland A. , Sullivan S. . ( 2009; ). Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA. . Vaccine 27:, 7409–7417. [CrossRef] [PubMed]
    [Google Scholar]
  60. Wald A. , Corey L. . ( 2003; ). How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?. J Infect Dis 187:, 1509–1512. [CrossRef] [PubMed]
    [Google Scholar]
  61. Wald A. , Zeh J. , Selke S. , Warren T. , Ashley R. , Corey L. . ( 2002; ). Genital shedding of herpes simplex virus among men. . J Infect Dis 186: (Suppl. 1), S34–S39. [CrossRef] [PubMed]
    [Google Scholar]
  62. Wald A. , Huang M. L. , Carrell D. , Selke S. , Corey L. . ( 2003; ). Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. . J Infect Dis 188:, 1345–1351. [CrossRef] [PubMed]
    [Google Scholar]
  63. Watson R. J. . ( 1983; ). DNA sequence of the herpes simplex virus type 2 glycoprotein D gene. . Gene 26:, 307–312. [CrossRef] [PubMed]
    [Google Scholar]
  64. Xu F. , Sternberg M. R. , Kottiri B. J. , McQuillan G. M. , Lee F. K. , Nahmias A. J. , Berman S. M. , Markowitz L. E. . ( 2006; ). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. . JAMA 296:, 964–973. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.040055-0
Loading
/content/journal/jgv/10.1099/vir.0.040055-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error